File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Current microfluidic platforms for reverse engineering of cornea

TitleCurrent microfluidic platforms for reverse engineering of cornea
Authors
Issue Date1-Apr-2023
PublisherElsevier
Citation
Materials Today Bio, 2023, v. 20, p. 100634 How to Cite?
AbstractAccording to the World Health Organization, corneal blindness constitutes 5.1% of global blindness population. Surgical outcomes have been improved significantly in the treatment of corneal blindness. However, corneal transplantation is limited by global shortage of donor tissue, prompting researchers to explore alternative therapies such as novel ocular pharmaceutics to delay corneal disease progression. Animal models are commonly adopted for investigating pharmacokinetics of ocular drugs. However, this approach is limited by physiological differences in the eye between animals and human, ethical issues and poor bench-to-bedside translatability. Cornea-on-a-chip (CoC) microfluidic platforms have gained great attention as one of the advanced in vitro strategies for constructing physiologically representative corneal models. With significant improvements in tissue engineering technology, CoC integrates corneal cells with microfluidics to recapitulate human corneal microenvironment for the study of corneal pathophysiological changes and evaluation of ocular drugs. Such model, in complement to animal studies, can potentially accelerate translational research, in particular the pre-clinical screening of ophthalmic medication, driving clinical treatment advancement for corneal diseases. This review provides an overview of engineered CoC platforms with respect to their merits, applications, and technical challenges. Emerging directions in CoC technology are also proposed for further investigations, to accentuate preclinical obstacles in corneal research.
Persistent Identifierhttp://hdl.handle.net/10722/328260
ISSN
2023 Impact Factor: 8.7
2023 SCImago Journal Rankings: 1.518
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLi, QY-
dc.contributor.authorWong, HL-
dc.contributor.authorIp, YL-
dc.contributor.authorChu, WY-
dc.contributor.authorLi, MS-
dc.contributor.authorSaha, C-
dc.contributor.authorShih, KC-
dc.contributor.authorChan, YK-
dc.date.accessioned2023-06-28T04:40:33Z-
dc.date.available2023-06-28T04:40:33Z-
dc.date.issued2023-04-01-
dc.identifier.citationMaterials Today Bio, 2023, v. 20, p. 100634-
dc.identifier.issn2590-0064-
dc.identifier.urihttp://hdl.handle.net/10722/328260-
dc.description.abstractAccording to the World Health Organization, corneal blindness constitutes 5.1% of global blindness population. Surgical outcomes have been improved significantly in the treatment of corneal blindness. However, corneal transplantation is limited by global shortage of donor tissue, prompting researchers to explore alternative therapies such as novel ocular pharmaceutics to delay corneal disease progression. Animal models are commonly adopted for investigating pharmacokinetics of ocular drugs. However, this approach is limited by physiological differences in the eye between animals and human, ethical issues and poor bench-to-bedside translatability. Cornea-on-a-chip (CoC) microfluidic platforms have gained great attention as one of the advanced in vitro strategies for constructing physiologically representative corneal models. With significant improvements in tissue engineering technology, CoC integrates corneal cells with microfluidics to recapitulate human corneal microenvironment for the study of corneal pathophysiological changes and evaluation of ocular drugs. Such model, in complement to animal studies, can potentially accelerate translational research, in particular the pre-clinical screening of ophthalmic medication, driving clinical treatment advancement for corneal diseases. This review provides an overview of engineered CoC platforms with respect to their merits, applications, and technical challenges. Emerging directions in CoC technology are also proposed for further investigations, to accentuate preclinical obstacles in corneal research.-
dc.languageeng-
dc.publisherElsevier-
dc.relation.ispartofMaterials Today Bio-
dc.titleCurrent microfluidic platforms for reverse engineering of cornea-
dc.typeArticle-
dc.identifier.doi10.1016/j.mtbio.2023.100634-
dc.identifier.hkuros344881-
dc.identifier.volume20-
dc.identifier.spage100634-
dc.identifier.eissn2590-0064-
dc.identifier.isiWOS:000989451300001-
dc.identifier.issnl2590-0064-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats